大行评级丨大摩：礼来口服减肥药临床试验数据亮眼 维持目标价1028美元

Core Viewpoint - Morgan Stanley's report indicates that Eli Lilly's oral GLP-1 receptor agonist, Orfor, demonstrates excellent performance in weight loss, improvement of cardiovascular metabolic indicators, and safety, maintaining a positive outlook on Orfor's prospects [1] Summary by Category - Performance Metrics - Orfor shows outstanding results in weight loss and cardiovascular metabolic improvements [1] - Safety profile of Orfor is also highlighted as impressive [1] - Market Outlook - The newly released data does not alter Morgan Stanley's positive view on Orfor's future [1] - The firm maintains an "Overweight" rating for Orfor with a target price of $1,028 over the next 12 months [1]